{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T07:53:54Z","timestamp":1768722834667,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["DTS16\/00115"],"award-info":[{"award-number":["DTS16\/00115"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/01689"],"award-info":[{"award-number":["PI16\/01689"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CP117\/00024"],"award-info":[{"award-number":["CP117\/00024"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CP14\/00173"],"award-info":[{"award-number":["CP14\/00173"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CP14\/00212"],"award-info":[{"award-number":["CP14\/00212"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R37-AA017447"],"award-info":[{"award-number":["R37-AA017447"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003751","name":"Ministerio de Sanidad, Servicios Sociales e Igualdad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bcp.2018.09.008","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T13:07:59Z","timestamp":1536239279000},"page":"235-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["PPAR\u03b1\/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models"],"prefix":"10.1016","volume":"157","author":[{"given":"Francisco","family":"Alen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Decara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Brunori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Bing","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kora-Mareen","family":"B\u00fchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Antonio","family":"L\u00f3pez-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Cippitelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Pavon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliot L.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Ciccocioppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Rodr\u00edguez de Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2018.09.008_b0005","unstructured":"World Health Organizaton. Global status report on alcohol and health \u2013 2014 ed. Luxembourg."},{"issue":"12","key":"10.1016\/j.bcp.2018.09.008_b0010","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/14656566.2017.1349098","article-title":"Pharmacotherapy of alcoholism \u2013 an update on approved and off-label medications","volume":"18","author":"Soyka","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bcp.2018.09.008_b0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/B978-0-444-62619-6.00003-3","article-title":"Neurocircuitry of alcohol addiction: synthesis from animal models","volume":"125","author":"Koob","year":"2014","journal-title":"Handb. Clin. Neurol."},{"issue":"3","key":"10.1016\/j.bcp.2018.09.008_b0020","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00213-013-3226-2","article-title":"Glutamatergic targets for new alcohol medications","volume":"229","author":"Holmes","year":"2013","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.bcp.2018.09.008_b0025","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjp.2008.30","article-title":"Neuropharmacology of alcohol addiction","volume":"154","author":"Vengeliene","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2018.09.008_b0030","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.euroneuro.2016.10.008","article-title":"Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy","volume":"26","author":"Mann","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2018.09.008_b0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pharmthera.2011.06.005","article-title":"Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors","volume":"132","author":"Serrano","year":"2011","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2018.09.008_b0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1042\/BJ20061898","article-title":"Regulation of brain anandamide by acute administration of ethanol","volume":"404","author":"Ferrer","year":"2007","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.bcp.2018.09.008_b0045","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00213-005-0199-9","article-title":"Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats","volume":"183","author":"Economidou","year":"2006","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.bcp.2018.09.008_b0050","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/adb.12276","article-title":"Role of the satiety factor oleoylethanolamide in alcoholism","volume":"21","author":"Bilbao","year":"2016","journal-title":"Addict. Biol."},{"key":"10.1016\/j.bcp.2018.09.008_b0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-018-0055-3","article-title":"Deficient endocannabinoid signaling in the central amygdala contributes to alcohol dependence-related anxiety-like behavior and excessive alcohol intake","author":"Serrano","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.bcp.2018.09.008_b0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.20882\/adicciones.728","article-title":"Psychiatric comorbidity and plasma levels of 2-acyl-glycerols in outpatient treatment alcohol users. Analysis of gender differences","volume":"29","author":"Garc\u00eda Marchena","year":"2016","journal-title":"Adicciones"},{"issue":"3","key":"10.1016\/j.bcp.2018.09.008_b0065","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/adb.12365","article-title":"Oleoylethanolamide prevents neuroimmune HMGB1\/TLR4\/NF-kB danger signaling in rat frontal cortex and depressive-like behavior induced by ethanol binge administration","volume":"22","author":"Ant\u00f3n","year":"2017","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2018.09.008_b0070","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/hep.24077","article-title":"Endocannabinoids in liver disease","volume":"53","author":"Tam","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2018.09.008_b0075","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/adb.12491","article-title":"Severity of alcohol dependence is associated with the fatty acid amide hydrolase Pro129Thr missense variant","volume":"23","author":"Sloan","year":"2018","journal-title":"Addict. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2018.09.008_b0080","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2174\/138955707781387920","article-title":"The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism","volume":"7","author":"Basavarajappa","year":"2007","journal-title":"Mini Rev. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2018.09.008_b0085","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1111\/j.1460-9568.2005.04056.x","article-title":"European TARGALC Consortium. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats","volume":"21","author":"Cippitelli","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bcp.2018.09.008_b0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fnbeh.2017.00133","article-title":"Fenofibrate administration reduces alcohol and saccharin intake in rats: possible effects at peripheral and central levels","volume":"11","author":"Rivera-Meza","year":"2017","journal-title":"Front. Behav. Neurosci."},{"issue":"7","key":"10.1016\/j.bcp.2018.09.008_b0095","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.biopsych.2010.12.010","article-title":"Activation of nuclear PPAR\u03b3 receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking","volume":"69","author":"Stopponi","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bcp.2018.09.008_b0100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neuropharm.2007.03.007","article-title":"The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats","volume":"54","author":"Serrano","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.09.008_b0105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature01921","article-title":"Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha","volume":"425(6953)","author":"Fu","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2018.09.008_b0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/bs.apha.2017.03.008","article-title":"The Role of Nuclear Hormone Receptors in Cannabinoid Function","volume":"80","author":"Pistis","year":"2017","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.bcp.2018.09.008_b0115","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.8b00159","article-title":"Classics in Chemical Neuroscience: risperidone","author":"Chopko","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"16","key":"10.1016\/j.bcp.2018.09.008_b0120","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1021\/acs.jmedchem.5b00849","article-title":"Novel oxazolidinone-based peroxisome proliferator activated receptor agonists: molecular modeling, synthesis, and biological evaluation","volume":"58","author":"Fresno","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2018.09.008_b0125","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/cmdc.201000161","article-title":"Synthesis of fatty acid amides of catechol metabolites that exhibit antiobesity properties","volume":"5(10)","author":"Almeida","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bcp.2018.09.008_b0130","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2017.09.007","article-title":"The novel dopamine D3 receptor antagonists\/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats","volume":"126","author":"You","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2018.09.008_b0135","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1242\/dmm.019919","article-title":"Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats","volume":"8(10)","author":"Decara","year":"2015","journal-title":"Dis Model Mech."},{"issue":"8","key":"10.1016\/j.bcp.2018.09.008_b0140","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.neuropharm.2005.02.013","article-title":"Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats","volume":"48","author":"Fu","year":"2005","journal-title":"Neuropharmacology"},{"issue":"11\u201312","key":"10.1016\/j.bcp.2018.09.008_b0145","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.lfs.2007.12.022","article-title":"Actions of 3-methyl-N-oleoyldopamine, 4-methyl-N-oleoyldopamine and N-oleoylethanolamide on the rat TRPV1 receptor in vitro and in vivo","volume":"82","author":"Alm\u00e1si","year":"2008","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.bcp.2018.09.008_b0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2006.02.004","article-title":"Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents","volume":"3","author":"Overton","year":"2006","journal-title":"Cell Metab."},{"issue":"19","key":"10.1016\/j.bcp.2018.09.008_b0155","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"issue":"5090","key":"10.1016\/j.bcp.2018.09.008_b0160","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.bcp.2018.09.008_b0165","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1523\/JNEUROSCI.21-14-05344.2001","article-title":"Functional interaction between opioid and cannabinoid receptors in drug self-administration","volume":"21","author":"Navarro","year":"2001","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.bcp.2018.09.008_b0170","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","article-title":"Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.bcp.2018.09.008_b0175","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.neuropharm.2012.06.046","article-title":"AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid\/cannabinoid interaction studies","volume":"63","author":"Seely","year":"2012","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.bcp.2018.09.008_b0180","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.biopsych.2016.12.029","article-title":"Nalmefene reduces reward anticipation in alcohol dependence: an experimental functional magnetic resonance imaging study","volume":"81","author":"Quelch","year":"2017","journal-title":"Biol. Psychiatry"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:05:15Z","timestamp":1762095915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218303903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":36,"alternative-id":["S0006295218303903"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.09.008","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPAR\u03b1\/CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}